Cetuximab plus FOLFOX for Patients with Metastatic Colorectal Cancer with Poor Performance Status and/or Severe Tumor-Related Complications
Introduction: Cetuximab-based chemotherapy showed a statistically significantly higher response rate compared with chemotherapy such as FOLFOX. Therefore, FOLFOX plus cetuximab is suspected to be the best regimen to alleviate tumor-related symptoms with a high response rate. Case Report: Here we pre...
Main Authors: | Kohei Shitara, Tomoya Yokota, Daisuke Takahari, Takashi Shibata, Yozo Sato, Masahiro Tajika, Takashi Ura, Kei Muro |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2010-07-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/319474 |
Similar Items
-
Long-term stable disease with mFOLFOX6 chemotherapy plus cetuximab for bone marrow metastasis from rectal cancer: A case report
by: Xiumei Fan, et al.
Published: (2023-01-01) -
Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
by: Takao Takahashi, et al.
Published: (2022-09-01) -
Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
by: Jesús García-Foncillas, et al.
Published: (2019-09-01) -
Treatment of Rectal Cancer-Induced Disseminated Carcinomatosis of the Bone Marrow with FOLFOX plus Cetuximab and Panitumumab
by: Takehito Ehara, et al.
Published: (2020-02-01) -
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
by: Alessandro Parisi, et al.
Published: (2021-10-01)